UNIQUE RESEARCH PROGRAMS

designed to meet the needs of many

A DISTINCTIVE PORTFOLIO OF COMPANIES

In building our portfolio, we continually evaluate the rare disease landscape and unmet needs. Each of our portfolio companies has a unique pipeline focusing on a distinct area of biology to address the great unmet need associated with “the long tail of disease.” Our programs are first-in-class and internally generated, each representing a pipeline-in-a-product opportunity that can treat numerous rare diseases.

Electra_logo

Electra Therapeutics is expanding the possibilities of targeting signal-regulatory protein (SIRP) to develop breakthrough therapies for immunological diseases and cancer.

We are currently interrogating numerous other areas of biology and continually building our portfolio. Details on additional portfolio companies will be coming soon.

THANK YOU

We look forward to connecting with you